Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Cancer Science
I Okamoto, K Nakagawa

Abstract

The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.

References

Jan 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kentaro InamuraYuichi Ishikawa
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kengo TakeuchiHiroyuki Mano
Dec 10, 2008·Proceedings of the National Academy of Sciences of the United States of America·Manabu SodaHiroyuki Mano
Apr 23, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kengo TakeuchiHiroyuki Mano
Apr 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Takaaki SasakiPasi A Jänne
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Oct 29, 2010·The New England Journal of Medicine·Young Lim ChoiUNKNOWN ALK Lung Cancer Study Group
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ken TakezawaKazuhiko Nakagawa
Sep 9, 2011·Science Translational Medicine·Kimio YonesakaPasi A Jänne
Nov 16, 2011·Therapeutic Advances in Medical Oncology·Yung-Jue Bang

❮ Previous
Next ❯

Citations

Mar 5, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Matthias PreusserPeter Birner
Oct 20, 2017·European Journal of Endocrinology·André Uchimura BastosJanete Maria Cerutti
Jul 5, 2019·Veterinary Surgery : VS·Scarlett M SumnerGary W Ellison
Sep 22, 2020·Expert Opinion on Drug Delivery·Archana UpadhyaAmbikanandan Misra
May 29, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keiichi OtaIsamu Okamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.